NewAmsterdam Pharma (NAMS) said late Wednesday it has priced an underwritten public offering of 12.1 million shares at $24.50 per share and pre-funded warrants to purchase 4.9 million shares at $24.4999 per warrant.
The company said it has also granted underwriters a 30-day option to purchase up to 2.6 million additional shares
The company said it expects gross proceeds from the offering, anticipated to close on Thursday, of $416.5 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.